In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
BioNTech quietly drops Claudin6 work
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
